From bioactive compound discovery and chromatographic fingerprinting to regulated clinical documentation, explore our turnkey contract research and raw material supply capabilities.
Global life-science brands face severe headwinds: compositional batch drift, tightening global pesticide thresholds, unverified adulteration, and lagging bioavailability. MedGence solves these friction points at an industrial scale.
Traditional crude extraction yields massive fluctuation in therapeutic fractions. We execute High-Performance Thin-Layer Chromatography (HPTLC) coupled with HPLC-DAD-MS to lock molecular identity markers, eliminating batch-to-batch discrepancies across raw botanical intake.
Regulatory frameworks across Europe and North America increasingly penalize neurotoxic solvent residues. We employ supercritical CO₂ extraction, aqueous countercurrent systems, and macroporous resin column chromatography.
Many promising botanical polyphenols, flavonoids, and ginsenosides suffer from poor aqueous solubility and intestinal permeability. Our CDMO division formulates specialized delivery formats that multiply human systemic absorption.
The global botanical extracts market is migrating rapidly from non-standardized commodity sourcing toward pharmacopeia-grade ODM contracts. Brands without robust CRO/preclinical validations risk severe recalls and regulatory rejection.
Global functional food and pharma brands are divesting from in-house extraction infrastructure. Escalating CapEx costs and stringent environmental policies mean tier-1 enterprises now partner with validated ODM botanical suppliers capable of orchestrating raw farm control, clinical dossiers, and cGMP commercial supply within a single contractual ecosystem.
Fragmented, broker-driven supply chains are unacceptable under modern pharmacovigilance audits. Global buyers require full botanical heritage mapping—spanning Good Agricultural and Collection Practices (GACP), field geo-coordinates, climatic harvesting records, and non-GMO cultivar verification.
The boundary between preventative dietary wellness and botanical therapeutics is dissolving. Regulatory bodies demand clinical endpoints (Phase I to IV safety and efficacy data) even for over-the-counter natural formulations. MedGence stands uniquely positioned to conduct these rigorous trials in tandem with mass production.
Exporting botanical sources requires navigating a labyrinth of pharmacopeial compendia, maximum residue limits (MRLs), and heavy metal constraints. We build bulletproof compliance dossiers for every target market.
Formulations intended for the United States conform to dietary supplement cGMP specifications. We assemble New Dietary Ingredient Notifications (NDIN) and Generally Recognized as Safe (GRAS) toxicological documentation.
Strict European adherence addressing pesticide screens covering 500+ compounds under GC-MS/MS and LC-MS/MS. Full compliance with European Pharmacopoeia (Ph. Eur.) monographs and EU Novel Food regulations.
Seamless pathway to Listed Medicine status in Australia (ARTG) and Natural Health Product (NHP) licensing in Canada. Comprehensive stability testing under ICH guidelines for climatic zones IVa and IVb.
Drawing on our track record of 56 registered hospital preparations in China, we facilitate localized translational clinical research and botanical drug dossier registration under National Medical Products Administration standards.
Our ODM solutions are engineered to directly integrate into modern finished product manufacturing lines, solving physical compatibility, chemical stability, and consumer sensory barriers.
Standardized extracts targeting alpha-glucosidase inhibition, hepatic glucose regulation, and AMPK pathway activation. Ideal for functional blood sugar stabilizing beverages, stick packs, and two-piece vegetarian capsules.
Botanicals focused on cortisol suppression, GABA receptor affinity, and neurotrophic factor (BDNF) upregulation. Manufactured under delicate temperature profiles to preserve delicate volatile aromatics and active steroidal lactones.
Sterile, endotoxin-screened botanical actives developed for transdermal delivery, anti-inflammatory cytokine suppression (TNF-α, IL-6), and elastase inhibition in high-end cosmetic serums and emulsions.
The boundary between natural botany and biotechnology is moving forward rapidly. Our research roadmap outlines how MedGence combines artificial intelligence screening with pilot-scale botanical extraction through 2026 and beyond.
Integration of molecular docking algorithms to predict botanical metabolite affinity with human nuclear receptors, reducing compound lead discovery timelines from 14 months to 6 weeks.
Commissioning of fully automated countercurrent extraction units with real-time NIR (Near-Infrared) inline spectroscopic concentration sensing to achieve 99.8% lot consistency.
Employing targeted bio-enzymes to convert rare minor ginsenosides and glycosylated flavonoids into bioavailable aglycone metabolites with 5-fold higher intestinal uptake.
Deployment of transcriptomic and metabolomic biomarker tracing across Phase II/III human trials, generating comprehensive mechanistic dossiers for pharmaceutical registration.
In-depth responses covering extraction kinetics, validation documentation, minimum order quantities, and IP ringfencing.
We do not rely on open-market spot commodities. We operate standardized botanical evaluation protocols measuring active metabolites across geographical origins, soil chemistries, and harvest windows. Our pilot assays pinpoint the peak harvest window and botanical plant part (e.g., rhizome vs. folium) to lock raw material potency prior to mass extraction.
Each batch is accompanied by an extensive Certificate of Analysis (CoA) containing HPTLC visual identity chromatograms, HPLC or GC quantitative assay curves, heavy metal analysis by ICP-MS (<10ppb sensitivity for Pb, Cd, As, Hg), microbiological testing under USP <2021/2022>, and pesticide multi-residue screenings adhering to USP <561> or Ph. Eur. 2.8.13.
All contract research and ODM projects operate under strict bilateral Non-Disclosure Agreements (NDA). Formulas, customized extraction parameter matrices, purification resins, and pilot equipment designs are ring-fenced. Client intellectual property remains exclusively client property, backed by audited secure server data retention and segmented manufacturing suites.
Yes. Unlike raw material traders, MedGence operates a full clinical research infrastructure. We conduct in vitro cellular screening, acute LD50 and chronic toxicity animal studies, and arrange GCP-compliant human clinical trials from small-scale pilot efficacy studies for dietary supplements to full Phase I-IV trials supporting new drug registrations.
Active ingredients can be provided as spray-dried standardized powders, freeze-dried active granules, vacuum-concentrated viscous extracts, pasty concentrates, and supercritical volatile oils. For finished formulations, our CDMO facilities supply two-piece hard capsules, softgels, micro-tablets, effervescent granules, and oral functional liquids.
Standard analytical method establishment and pilot laboratory extraction take approximately 4 to 8 weeks. Preclinical in vitro evaluation requires 6 to 10 weeks. Industrial scale-up trials and commercial validation batches take 8 to 12 weeks. Complete projects transitioning from initial plant screening to commercial shipping average 6 months depending on regulatory dossier depth.
Select a specialized capability to initiate technical feasibility reviews, request reference chromatograms, or book a consultation with our senior phytochemists.
